Skip to main content
. 2022 Feb 15;10(2):E200–E208. doi: 10.1055/a-1675-2334

Table 3. Overall survival rates.

Overall survival rates P
1 year 3 years 5 years
Total 87.29 ± 0.78 68.16 ± 1.15 58.59 ± 1.29 –
group  < 0.001

  • Advanced ESCC 1

60.19 ± 8.59 25.34 ± 7.72 11.40 ± 5.90

  • Superficial ESCC 2

90.75 ± 2.45 67.44 ± 4.12 54.75 ± 4.61

  • No ESCC

 87.53 ± 0.82 69.10 ± 1.20 60.05 ± 1.35
Subgroup  < 0.001

  • Advanced ESCC 3

60.19 ± 8.59 25.34 ± 7.72 11.40 ± 5.90

  • Intramucosal carcinoma

 91.49 ± 4.70 63.90 ± 8.37 51.68 ± 9.33

  • Submucosal carcinoma

 94.12 ± 5.71 74.12 ± 11.41 74.12 ± 11.41

  • High-grade dysplasia

 89.96 ± 3.89 66.95 ± 6.48 52.21 ± 7.34

  • Low-grade dysplasia

 89.66 ± 5.66 68.14 ± 8.78 53.16 ± 9.53

  • Non-dysplastic lesions

 90.44 ± 1.54 72.64 ± 2.42 64.24 ± 2.71

  • No lesion

 86.69 ± 0.95 68.10 ± 1.38 58.81 ± 1.55

P , log rank test; ESCC, esophageal squamous cell carcinoma.

1

Advanced ESCC versus superficial ESCC p < 0.001. Advanced ESCC versus no ESCC P  < 0.001.

2

Superficial ESCC versus no ESCC P  = 0.210

3

Advanced ESCC versus all others groups P  < 0.001.